Recombinant Chinese Hamster Ovary Cell Market - Forecast(2024 - 2030)

Key Takeaways

• Geographically, the North America Recombinant Chinese Hamster Ovary Cell Market accounted for the highest revenue share in 2021. The growth is owing to state-of-the-art research facilities and top-flight professionals.

• Technological breakthroughs, heightening research spending in both developed and developing countries, and spiraling prevalence of infectious ailments are said to be preeminent drivers driving the growth of the Recombinant Chinese Hamster Ovary Cell Market. Exorbitant research activities, hampered operations because of the COVID, and the dearth of enough skilled professionals are said to reduce the market growth.

• Detailed analysis of the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Recombinant Chinese Hamster Ovary Cell Market report.

Recombinant Chinese Hamster Ovary Cell Market Share, By Geography (%) in 2021

For more details on this report - Request for Sample

Recombinant Chinese Hamster Ovary Cell Market Segment Analysis-By Applications

The Recombinant Chinese Hamster Ovary Cell Market based on the applications can be further segmented into biotherapeutic and API production, Genetic studies, Gene expression, Toxicity screening, and Others. The biotherapeutics and active pharmaceutical ingredients production segment held the largest share in 2021. The growth is owing to the growing prevalence of vaginal infections, cancer, Clostridium difficile infections, and other chronic illnesses. Biopharmaceutics is termed medicines that are manufactured with the help of biological means, and they play a significant role in treating the aforementioned health complications. Active pharmaceuticals are the base of every medicine produced anywhere in the world. Therefore, without their production, it won’t be possible for companies to manufacture medicinal drugs. As a result, considering the proliferating swell in acute and chronic maladies the same segment is estimated to be the fastest-growing segment with a CAGR of 6.6% over the forecast period 2022-2027.

Recombinant Chinese Hamster Ovary Cell Market Segment Analysis-By End-User

The Recombinant Chinese Hamster Ovary Cell Market based on end-user can be further segmented into CROs, Biopharmaceutical companies, Research laboratories or institutes, and Others. The biopharmaceutical companies segment held the largest share in 2021. The growth is owing to the rising demand for better and more effective therapeutics as several infectious diseases are roaming around the world. Therefore, biopharmaceutical companies have ramped up their efforts to develop novel therapeutics. Similarly, the biopharmaceutical segment is estimated to be the fastest-growing with a CAGR of 6.8% over the forecast period 2022-2027. This growth is owing to the rising means and expertise of companies to better execute their operations as they are undergoing several mergers and acquisition activities. In addition to that, CHO cells' significance in inspecting genetic mutations has provided several growth opportunities to the aforementioned market in the said segment.

Recombinant Chinese Hamster Ovary Cell Market Segment Analysis-By Geography

The Recombinant Chinese Hamster Ovary Cell Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 40% of the overall market in 2021. The growth in this segment is owing to the factors such as well-established healthcare infrastructure and economic affluence. The American healthcare infrastructure is deemed to be the best in the world. Moreover, the US is home to several world-renowned research facilities and academic institutions such as Harvard, Stanford, and MIT. Moreover, quality lifestyles and sound salary packages have helped developed countries like Canada and the US to attract top-notch talent from around the globe. However, Asia-Pacific is expected to be the fastest-growing segment over the forecast period 2022-2027. This growth is owing to bettering healthcare infrastructure as Asia is emerging as the new wealth center of the world. Governments of various developing nations such as India, China, and Indonesia are allocating comfortable packages to ameliorate existing infrastructure.

Recombinant Chinese Hamster Ovary Cell Market Drivers

The overall demand for biotherapeutics has witnessed an unprecedented surge in recent years as the world reeling under the weight of several infections and severe illnesses like cancer. Millions have lost their lives because of COVID-19. On another hand, cancer has become a headache, especially in developed countries like the US. In 2021, nearly 1.9 million cases and over 608,500 deaths were reported in the US. On another hand, with expanding acute health complications, the over usage of antibiotics has resulted in a high prevalence of clostridium difficile infection. According to toa report, around 200,000 people in the US develop this condition every year. Therefore, the high demand for CHO cells has heightened the growth of the recombinant Chinese hamster ovary cell market.

Augmenting research spending in developing countries is expected to boost market demand.

Refining healthcare infrastructure and growing economic prosperity have been prime stimuli for the recombinant Chinese hamster ovary cell market. As developing countries like China are achieving new export milestones despite the pandemic, the government has more means to spend on healthcare amelioration and research activities. With a 6.09 percent rise, China spent nearly $26.84 billion on research and development in 2021. Moreover, the Chinese government allocating staggering packages to ramp up the existing healthcare infrastructure.

Recombinant Chinese Hamster Ovary Cell Market Challenges

The dearth of skilled professionals, extortionate research activities, and hampered research operations are Anticipated to hamper the market growth.

The requirement of well-established and world-class laboratories is the biggest prerequisite for executing research activities effectively. However, setting up such facilities requires an innumerable flow of hard cash which the majority of the developing and underdeveloped countries can not afford. According to Edelweiss, there are around 1,216 NABL accredited labs, which is ~1% of total labs in India and works out to less than 1 lab per million. The top 4 players have the maximum number of NABL accredited labs. Though the number of accredited labs in India has been growing at 16% CAGR to 1,216 in 2020 from 576 in 2015, there is still a long way to go to reach the numbers of peer nations such as the UK, US, and Australia, which have more than 10 labs per million. Moreover, too often brilliant minds from underdeveloped worlds flee to developed nations in order to lead a quality lifestyle which eventually impacts poor countries adversely. On another hand, the shortage of top-flight and highly skilled professionals is another major factor that challenges the steady growth of the aforementioned market.

Recombinant Chinese Hamster Ovary Cell Industry Outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the aforementioned Market. Recombinant Chinese Hamster Ovary Cell market top 10 companies include-

1. WuXi Biologics
2. Celonic Group
3. Thermo Fisher Scientific
4. Selexis SA
5. Merck
6. JSR Life Sciences
7. Cygnus Technologies
8. Trenzyme GmbH
9. ProBioGen
10. LakePharma

Recent Developments

• On September 3, 2021, Curia (a New York, United States-based contract research, development, and manufacturing organization (CDMO) known for its drug development services) announced that it has successfully acquired California, United States-based biologics CRDMO “LakePharma.” The acquisition has strengthened the fill-finish and drug substance manufacturing expertise of Curia.

• On May 7, 2021, China-based contract research, development, and manufacturing organization WuXi Biologics announced the 3 successful acquisitions. the company publicized the acquisition of Jiangsu-based CMAD Biopharma group and manufacturing facility from US-based pharmaceutical company Pfizer and German life sciences company Bayer.

• On April 15, 2021, Massachusetts, United States-based firm Thermo Fisher Scientific (a company that supplies various scientific instruments and reagents, and consumables) announced the successful acquisition of PPD (a North Carolina, United States-based CRO committed to drug development). Thermo Fisher made an overwhelming payment of $17.4 billion in order to complete the acquisition.

Relevant Links: